Minkyu Park

Minkyu represents issuers and underwriters on various capital markets transactions – spanning initial public offerings (IPOs), equity follow-on offerings, private investment in public equity (PIPE) financings, debt offerings and liability management transactions. Minkyu also represents domestic and foreign public companies in connection with their Securities and Exchange Commission (SEC) reporting and corporate governance matters.

Before law school, Minkyu served in the Korean military battalion of the United Nations Interim Force in Lebanon to conduct peacekeeping operations.

Minkyu’s representative equity transactions:

• Evommune in its $173 million IPO
• LB Pharmaceuticals in its $328 million IPO
• Abivax in its $236 million IPO and $748 million equity follow-on offering
• Keros Therapeutics in its $161 million equity follow-on offering
• Tectonic Therapeutics in its $185 million PIPE
• VYNE Therapeutics in its $88 million PIPE
• The underwriters in Caris Life Science’s $568 million IPO
• The underwriters in NewAmsterdam Pharma’s various equity follow-on offerings
• The underwriters in Rent the Runway’s $357 million IPO
• The underwriters in Cerevel Therapeutics’ $254 million equity follow-on offering and concurrent $345 million convertible notes offering
• The underwriters in Verona Pharma’s $150 million equity follow-on offering

Minkyu’s representative debt transactions:

• Jazz Pharmaceuticals in its $1 billion convertible notes offering
• The underwriters in Jefferies Financial Group’s $1.5 billion and $1 billion investment-grade notes offerings
• The underwriters in Vizsla Silver’s $300 million convertible notes offering
• The underwriters in Ur-Energy’s $120 million convertible notes offering
• The underwriters in Semler Scientific’s $100 million convertible notes offering
• The underwriters in McEwen Minings’ $110 million convertible notes offering